Kernal Biologics to Present at the 9th CAR-TCR Summit
CAMBRIDGE, Mass., September 18, 2024, Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing immunotherapies designed to improve patients' survival rate and quality of life — today announced it is presenting in person at the 9th CAR-TCR Summit in Boston, MA.
"Kernal Bio's mRNA LNP 2.0 platform is ideally suited for cell-specific therapeutic applications. We have recently collected exciting data on our T-cell-specific mRNA LNPs. Recently, we paired these mRNA LNPs with CAR payloads for B-cell depletion. We look forward to showcasing our platform with the KR-402 program, which has shown effective B-cell depletion in vivo," said Kernal Bio Co-founder and Chief Executive Officer Yusuf Erkul, M.D., M.B.A.
On Day 1 of the conference (Wednesday 18th), Dr. Erkul will introduce Kernal Bio's platform and present data from the company's first in vivo CAR-T program, KR-402. In addition to in vitro and in vivo characterization of KR-402, the company will discuss analytical considerations for targeted mRNA LNPs.
Details for the Khttps://kernalbio.com/admin/module/2084/list-viewernal Bio presentation are as follows:
Presentation Title: Characterization of T-cell targeted CAR mRNA LNPs
Presenter: Yusuf Erkul, M.D., M.B.A.
Time: 1.40 PM, September 18, 2024
Place: Boston, MA
About Kernal Biologics, Inc.
Kernal Bio is pioneering the engineering of human cells inside the body using selective mRNA-LNP technology to fight cancer and autoimmune diseases. By delivering antibody-decorated lipid nanoparticles (LNPs) that precisely target specific cell types, AI-designed mRNAs ensure high specificity and minimize off-target effects within the body. Kernal Bio has demonstrated remarkably high in vivo delivery efficiency (>90%) with our T-cell-targeted mRNA LNPs. Recently, by deploying these for in situ CAR T programming, the company achieved successfully in vivo B-cell depletion within a week. KR-402 program is being developed for hematological malignancies and autoimmune disorders. The cancer cell-targeting program, KR-335, boasts a 100x therapeutic index, showing high efficacy in solid tumors resistant to conventional immuno-oncology agents. It demonstrated strong tolerability in preclinical models, including mice and non-human primates. With roots in MIT, Harvard, Merck, and BMS, the management team has led the way with three FDA-approved therapies and 120+ patents. Based in Cambridge, MA, and backed by investors like Hummingbird Ventures, Amgen Ventures, and NASA, Kernal Bio is revolutionizing mRNA therapeutics by harnessing AI to direct precision treatments within the body.
About the mRNA2.0 Platform
Kernal Bio is at the forefront of mRNA therapeutics and synergistically exploits targeted LNP (lipid nanoparticle) delivery and cell-selective translation of its synthetic mRNA, controlling the amount and site of protein produced, without the need for any genetic editing or the risk of genomic integration. Our proprietary best-in-class decorated lipid nanoparticle technology allows us to achieve in situ cell engineering via systemic, targeted, extra-hepatic delivery to specific tissues and cells, such as T cells. The delivery capability, combined with the translation of cell-selective mRNA, eliminates off-target effects. This expertise is enabled by Kernal Bio’s proprietary machine learning (ML) powered platform that discovers RNA sequence motifs from clinical human data with preferential translation based on cell type.
Source: Kernal Biologics, Inc.